Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
SOLUTION
**\[Dosage and Administration\]** Usually, instill 1 drop a time 3 times daily. The dosage may be adjusted according to the patient's symptoms.
OPHTHALMIC
Medical Information
**\[Indications\]** The following infections caused by levofloxacin-susceptible strains of _Staphylococcus_ sp., _Streptococcus_ sp., _Streptococcus pneumoniae_, _Micrococcus_ sp., _Enterococcus_ sp., _Corynebacterium_ sp., _Pseudomonas_ sp., _Pseudomonas aeruginosa_, _Haemophilus_ sp. ( _H. influenzae, H. aegyptius_ \[ _Koch-Weeks bacillus_\]), _Moraxella_ ( _Branhamella_) _catarrhalis_, _Moraxella_ sp. ( _Morax-Axenfeld bacillus_), _Serratia_ sp., _Klebsiella_ sp., _Proteus_ sp., _Acinetobacter_ sp., _Enterobacter_ sp,. _Propionibacterium acnes_ : Blepharitis, hordeolum, dacryocystitis, conjunctivitis, tarsadenitis, keratitis, corneal ulcer, and postoperative infections.
**\[Contraindications\] (Cravit ophthalmic solution is contraindicated in the following patients.)** Patients with a history of hypersensitivity to the ingredient of this product, Ofloxacin or any quinolone antibiotics.
S01AX19
xs 01 ax 19
Manufacturer Information
SANTEN PHARMACEUTICAL ASIA PTE. LTD.
Santen Pharmaceutical Co., Ltd (Noto Plant)
Active Ingredients
Documents
Package Inserts
CV_SG_BN_PI_191029.pdf
Approved: March 19, 2020